BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• Press Releases

  STRATA Skin Sciences’ TheraClear®X Acne Therapy System Found Safe and Effective in Study Published in Peer Reviewed Journal

  July 18, 2024

   · 

  6 min read
• Press Releases

  Bon Secours Mercy Health and Philips sign multi-year strategic collaboration

  July 18, 2024

   · 

  4 min read
• Press Releases

  Globus Medical Receives FDA 510(k) Clearance for ExcelsiusFlex™ and ACTIFY™ 3D Total Knee System

  July 18, 2024

   · 

  6 min read
• Press Releases

  Sumitomo Corporation of Americas Investment in Vast Medical Holdings; Marks Entry into U.S. Healthcare Market with Goals to Improve Patient Outcomes

  July 18, 2024

   · 

  4 min read
• Press Releases

  HSS Appoints Constantine A. Demetracopoulos, MD, Chief of Foot and Ankle Service

  July 18, 2024

   · 

  3 min read
• Press Releases

  Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma

  July 18, 2024

   · 

  8 min read
• Press Releases

  EveryLife Statement on the Creation of FDA Rare Disease Innovation Hub

  July 18, 2024

   · 

  3 min read
• Press Releases

  Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A

  July 18, 2024

   · 

  9 min read
• Press Releases

  Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

  July 18, 2024

   · 

  9 min read
• Press Releases

  BioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHD

  July 18, 2024

   · 

  7 min read